Orion Oyj operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Orion Oyj with three other
pharmaceutical manufacturers in Europe:
Indivior Plc
of the United Kingdom
(2017
sales of £839.48 million [US$1.20 billion]
of which 100%
was Buprenorphine Based Drugs),
Vifor Pharma AG
of Switzerland
(1.34 billion Swiss Francs [US$1.39 billion]
of which 100%
was Pharmaceutical), and
Krka DD Novo Mesto
which is
based in Slovenia
(1.27 billion Euro [US$1.57 billion]
).
Sales Analysis.
During the year ended December of 2017, sales at
Orion Oyj were 1.08 billion Euro (US$1.34 billion).
This
is
a very small
increase of 1.0%
versus 2016, when the company's sales were 1.07 billion Euro.
This was the fifth consecutive year of sales increases at Orion Oyj
(and since 2012, sales have increased a total of 11%).
Sales of Pharmaceuticals Business saw an increase
of
1.2% in 2017, from
1.02 billion Euro to 1.03 billion Euro.
Not all segments of Orion Oyj experienced an increase in sales in 2017:
sales of Diagnostica fell 1.8% to 53.80 million Euro.